相关实验视频

Updated: Jul 25, 2025

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector

Published on: February 28, 2016

在帕金森病中-同核素聚合物的向降解使用AUTOTAC技术

Jihoon Lee^1,2,3, Ki Woon Sung^1,2,3, Eun-Jin Bae^2,4

¹Cellular Degradation Biology Center, College of Medicine, Seoul National University, Seoul, 03080, Republic of Korea.

Molecular neurodegeneration

|June 24, 2023

概括

这项研究介绍了AUTOTAC,一种使用ATC161选择性降解α-synuclein聚合物的新方法,为帕金森病 (PD) 提供了潜在的疾病修饰疗法. 在临床前模型中,ATC161通过清除有毒聚合物和改善运动功能,显示出有希望的结果.

科学领域:

神经科学是一个神经科学.
生物化学生物化学
药理学药理学是指药理学的学科.

背景情况:

帕金森病 (PD) 缺乏改变疾病的治疗方法,而α-syn聚合物驱动病理.
目前的治疗策略在消除有毒α-syn聚合物的能力上是有限的.
化向金马 (PROTAC) 方法在降解聚合蛋白质方面面临着挑战.

研究的目的:

开发一种针对帕金森病中的α-syn聚合物的新疗法.
为了评估AUTOTAC (自-向奇美拉) 在降解α-syn聚合物的有效性.
评估ATC161作为PD的口服药物的治疗潜力.

主要方法:

利用AUTOTAC,一个基于宏自的向蛋白质降解平台.
合成的AUTOTAC化合物,旨在结合α-syn聚合物和p62受体.
在PD的细胞和小鼠模型中通过p62-依赖的宏自来评估α-syn聚合物的降解.
研究药理动力学/药理动力学 (PK/PD) 用于口服药物开发.

主要成果:

选择性降解的高强度 (DC50~100nM) 的α-syn聚合物,节省单体α-syn.
ATC161促进了α-syn聚合物的向溶酶体以通过p62.2.降解降解.
在PD模型中,ATC161降低了α-syn传输,防止细胞损伤,缓解神经炎症,并改善了小鼠的运动功能.
在口服时,ATC161表现出有利的PK/PD概况.

结论:

AUTOTAC代表了一个可行的平台,用于开发新的帕金森病治疗方法.
在体外和体内,ATC161有效降解致病性α-syn聚合物.
建议ATC161作为帕金森病的疾病修饰药物候选药物,针对病理的根本原因.

关键词:

lysosome 是一个溶解体.宏观自的过程有针对性的蛋白质降解降解.这是N-degron路径.自-溶解体系统的自-溶解体系统.p62/SQSTM1/Sequestosome-1 组合组合组合组合组合组合组合组合组合组合组合组合

更多相关视频

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Targeting Alpha Synuclein Aggregates in Cutaneous Peripheral Nerve Fibers by Free-floating Immunofluorescence Assay

Published on: June 25, 2019

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

相关概念视频

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Autophagy

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...